IGF2BP3 and neuroblastoma: As for survival analysis, in all the NB patients, we found thatIGF2BP3 (log-rank p = 0.008, HR = 1.76, 95% CI 1.16-2.67), METTL14 (log-rank p = 0.005, HR = 1.84, 95% CI 1.21-2.8), and METTL16 (log-rank p = 0.01, HR = 0.579, 95% CI 0.381-0.879) are prognostic factors for DFS (Figure 6) while IGF2BP3 (log-rank p = 0.033, HR = 1.55, 95% CI 1.03-2.31), METTL14 (log-rank p = 0.038, HR = 1.53, 95% CI 1.02-2.3), and METTL16 (log-rank p = 0.003, HR = 0.534, 95% CI 0.354-0.806) are prognostic factors for OS (Figure 7).